InflaRx weighs broader Europe AAV strategy, plans EMA talks on vilobelimab and izicopan

InflaRx N.V.

InflaRx N.V.

IFRX

0.00
  • InflaRx is weighing a broader Europe development and registration strategy for ANCA-associated vasculitis following an EMA panel move to revoke Tavneos.
  • Plans regulatory talks with the EMA on vilobelimab, alongside oral candidate izicopan, to map a potential approval pathway in AAV.
  • Work continues on Phase 2 planning for izicopan in AAV across multiple geographies, without changes.
  • Goal is to select the most efficient development plan to bring C5a/C5aR inhibition to AAV patients in Europe.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inflarx NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606300730PRIMZONEFULLFEED9754667) on June 30, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.